Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00878878 · ClinicalTrials.gov registry record · Phase 4
Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR).
A Phase 4 study, sponsored by GE Healthcare.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT00878878 is a Phase 4 study that has completed, run by GE Healthcare. The registered enrollment target is 30 participants.
The verdict
NCT00878878, a Phase 4 study, has completed, sponsored by GE Healthcare.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
The design of this study is to conduct a comprehensive safety evaluation of the pulmonary hemodynamic effects of Optison. The study is being conducted in subjects referred for cardiac catheterization for clinical reasons.
Interventions
- DRUG Dextrose
- DRUG Optison (Perflutren Protein-Type A Microspheres Injectable Suspension)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2009-03 |
| Est. Completion | 2010-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00878878
The ClinicalTrials.gov registry entry for NCT00878878 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GE Healthcare, which has 99 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dextrose is the first listed.
NCT00878878 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00878878 about?
NCT00878878 is a clinical study titled "Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR).". The design of this study is to conduct a comprehensive safety evaluation of the pulmonary hemodynamic effects of Optison. The study is being conducted in subjects referred for cardiac catheterization for clinical reasons.
What is the current status of trial NCT00878878?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2009-03. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00878878?
The interventions under investigation include: Dextrose (DRUG), Optison (Perflutren Protein-Type A Microspheres Injectable Suspension) (DRUG).
Who is sponsoring clinical trial NCT00878878?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.